Navigation Links
Women More Persistent with Monthly Osteoporosis Treatment

Once a month osteoporisis drug and extra telephone support from trained nurses has met with 47 per cent greater persistence among women for their drug treatment// than those who took a weekly tablet, according to a study in the August issue of IJCP, the International Journal of Clinical Practice.

103 primary care centres across the UK took part in the PERSIST study between January 2005 and January 2006, with 1,076 women each agreeing to participate for a six-month period.

542 were prescribed a single 70mg dose of alendronate once a week and the remainder received a single monthly 150mg dose of ibandronate and were enrolled in a free patient support programme designed to complement the drug.

The monthly ibandronate group received a welcome pack providing basic information about osteoporosis and a monthly reminder call from a trained nurse one to three days before the dose was due.

The nurses also used the opportunity to confirm dosing instructions, provide further information about osteoporosis and stress the importance of adhering to the treatment regime.

835 women completed the study, leaving 440 in the monthly ibandronate group and 395 in the weekly alendronate group.

Of these, just under 57 per cent of patients receiving monthly ibandronate tablets, together with patient support, were taking the medication after six months. The persistence rate for patients on weekly alendronate tablets was 39 per cent.

"Getting patients to continue taking prescribed medication is a major problem for healthcare professionals" says lead author Dr Alun Cooper, a family doctor from the Bridge Medical Centre in Crawley, UK.

"The World Health Organization estimates that only 50 per cent of patients with chronic diseases in developing countries stick to treatment regimes. And the American Heart Association has identified failing to take medication correctly as the number one problem in treating ill health today.

According to the International Osteoporosis Foundation one in three women over 50 suffer from osteoporosis worldwide.

"Sufferers find that their bones become increasingly brittle and this increases the risk of serious factures, especially if they don't take their medication on a regular basis" says Dr Cooper. "It's estimated that one in two women over 50 will experience a fracture at some time because of fragile bones, so any treatment regime that improves compliance is to be welcomed."

The women who took part in the study had an average age of 68 and more than a third had a family history of osteoporosis.

45 per cent had already suffered a fracture, with just under a third reporting one incident and a further ten per cent reporting two. Four per cent had experienced three to five factures.

"Our study clearly shows that women who were prescribed monthly doses of ibandronate, and enrolled on a patient support programme, were much more likely to continue taking their medication than those on weekly doses of alendronate" concludes Dr Cooper.

"Evidence suggests that adhering to regular treatment for osteoporosis improves bone mass density and reduces fracture rates. This, in turn, reduces the social and economic burden of this very common and debilitating chronic condition."

Source Eurekalert
'"/>




Related medicine news :

1. Women suffer from sexual dysfunction too
2. Women find difficulty in calling it Quits
3. Women recognise faces better
4. Women more susceptible to brain damage from ecstasy
5. Good News For Women With Gestational Diabetes
6. Unsatisfactory Grade On Womens Health Issues
7. Risk for Pregnant Women
8. Womens strong sense of smell
9. Women need to exercise more to prevent obesity
10. Women benefit from consuming fish
11. Women are at risk with raised cholesterol
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of ... However, for those self-conscious about a double chin, this means more anxiety than elation. ... , “For most people, a double chin is undesirable,” Dr. Goldman said, “but ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical group Allied ... as new board chair for Orange County health care system CalOptima Friday. CalOptima ... soon-to-be former chair Mark Refowitz’s term, which runs through June 30 of this ...
(Date:3/28/2017)... ... , ... With less than 10,000 dermatologists in the United States and more ... while the desire to conquer breakouts and eliminate skincare stress is widespread. Curology ... today released its inaugural survey on the State of Acne in America. , ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... The Executives, ... to raise money to for the Toys for Tots Literacy Campaign at their Semi-Annual ... in excess of $70 billion, the U.S. ranks at number 14 internationally in literacy. ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... which will be offered by the American Association of Integrative Medicine and available ... for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
(Date:3/28/2017)... Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today ... Christopher Gabrieli , partner emeritus ... of the board of Akcea Therapeutics. ... Sandford D. Smith , founder and ... are excited to announce this expansion to our board and ...
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
Breaking Medicine Technology: